J&J Reports Sustained Response for Its Psoriasis Drug
Johnson & Johnson reports sustained response for its psoriasis drug, a durability claim that shifts the conversation from rapid clearance to long-term maintenance in a crowded biologic field.
Topic
Johnson Johnson
Topic
Johnson Johnson
Icotrokinra Holds Up at Two Years in Plaque Psoriasis
Johnson & Johnson reports robust two-year data for ICOTYDE (icotrokinra) in plaque psoriasis across adults and adolescents, posit…
FDA Clears First-of-its-Kind Oral Psoriasis Therapy from J&J
Johnson & Johnson has won approval for a first-of-its-kind psoriasis pill, a regulatory decision that adds a novel oral optio…
J&J Psoriasis Drug Holds Clearance Through Two Years
Johnson & Johnson's psoriasis therapy sustained skin clearance through two years of follow-up, according to a MyChesCo report. Th…
J&J Oral Psoriasis Therapy Holds 70% Clear Rate at Two Years
Johnson & Johnson's investigational oral psoriasis pill held clear or almost clear skin in at least 70% of patients at two years,…
J&J Brings Two-Year Psoriasis Data to Dermatology Meeting
Johnson & Johnson presented two-year psoriasis drug data at a dermatology meeting, extending long-term evidence for its inflammat…
J&J Reports 72% PASI 90 Response Held at Two-Year Mark
Johnson & Johnson has reported that at least 72% of patients in a long-term psoriasis cohort hit PASI 90 at two years. Here's wha…
89% of Psoriasis Patients on J&J Pill Report Clear Genital Skin at Two Years
Two-year data for J&J's oral psoriasis therapy show 89% of patients achieved clear skin in previously affected genital areas, add…
Icotrokinra Sustains High-Impact Site Clearance at 2 Years
Two-year ICONIC-TOTAL extension data show icotrokinra sustains clearance of high-impact psoriasis sites — scalp, face, palms, sol…
J&J Reports Two-Year Icotrokinra Durability Data in Plaque Psoriasis
J&J reports two-year icotrokinra durability data in difficult-to-treat plaque psoriasis, positioning the oral agent as a first-li…